Eton Pharmaceuticals Gains After Securing U.S. Rights to Ultra-Rare Disease Candidate
Eton Pharmaceuticals' shares climbed after the company obtained U.S. marketing rights to an ultra-rare disease product candidate currently under FDA review. If approved, the product would be the first generic alternative for a condition impacting fewer than 100 patients in the United States and is slated for a mid-2026 launch and integration into E…